Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Zacks News
Accuray's New CyberKnife S7 System to Boost Patient Care
by Zacks Equity Research
Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block
by Zacks Equity Research
With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
Encompass Health to Build Rehabilitation Hospital in Illinois
by Zacks Equity Research
Encompass Health (EHC) plans to build a rehabilitation facility in Illinois to serve the local community. The healthcare home will be launched in 2022 spring and complement other units in the area.
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
Here's Why You Should Hold on to Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.
AMN Healthcare (AMN) Introduces New Customizable Offering
by Zacks Equity Research
AMN Healthcare (AMN) offers a customizable return-to-work solutions as businesses resume operations amid the ongoing pandemic.
Abbott's (ABT) FreeStyle Libre Study Outcome Favorable
by Zacks Equity Research
The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.
Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy
by Zacks Equity Research
Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy
Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks
by Aniruddha Ganguly
Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.
4 Stocks With Upgraded Broker Ratings Worth Betting on Now
by Swayta Shah
By following broker ratings, you can find stocks that are likely to generate solid returns.
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
DGX vs. EHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DGX vs. EHC: Which Stock Is the Better Value Option?
Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA
by Zacks Equity Research
This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.
Why Is Quest Diagnostics (DGX) Up 12.3% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Info Systems Outlook Bright Amid Coronavirus Crisis
by Urmimala Biswas
Despite the coronavirus-led worldwide sales disruption, Medical Info Systems is one of the few sectors witnessing industry-wide growth.
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Quest Diagnostics (DGX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 13.25% and 4.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.